{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:06:31Z","timestamp":1794373591709,"version":"4.9.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Beijing xisike clinical oncology research foundation","award":["Y-HS2017-043"],"award-info":[{"award-number":["Y-HS2017-043"]}]},{"name":"Beijing xisike clinical oncology research foundation","award":["Y-BMS-2019-100"],"award-info":[{"award-number":["Y-BMS-2019-100"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.survophthal.2020.09.004","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T07:27:15Z","timestamp":1601018835000},"page":"461-470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Clinical treatment options for early-stage and advanced conjunctival melanoma"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0135-8103","authenticated-orcid":false,"given":"Yue","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lishu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxiang","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.survophthal.2020.09.004_bib1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2165\/00003495-200666030-00005","article-title":"Mitomycin: clinical applications in ophthalmic practice","volume":"66","author":"Abraham","year":"2006","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.survophthal.2020.09.004_bib2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.amjoto.2019.05.013","article-title":"Prognostic factors and survival for malignant conjunctival melanoma and squamous cell carcinoma over four decades","volume":"40","author":"Abt","year":"2019","journal-title":"Am J Otolaryngol"},{"issue":"6","key":"10.1016\/j.survophthal.2020.09.004_bib3","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/eye.2016.322","article-title":"Fresh frozen amniotic membrane for conjunctival reconstruction after excision of neoplastic and presumed neoplastic conjunctival lesions","volume":"31","author":"Agraval","year":"2017","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.survophthal.2020.09.004_bib4","series-title":"AJCC Cancer Staging Manual","year":"2017"},{"key":"10.1016\/j.survophthal.2020.09.004_bib5","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ejmech.2016.01.012","article-title":"PI3K\/Akt\/mTOR and Ras\/Raf\/MEK\/ERK signaling pathways inhibitors as anticancer agents: structural and pharmacological perspectives","volume":"109","author":"Asati","year":"2016","journal-title":"Eur J Med Chem"},{"issue":"4","key":"10.1016\/j.survophthal.2020.09.004_bib6","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000381719","article-title":"Management of conjunctival melanoma: critical assessment of sentinel lymph node biopsy","volume":"1","author":"Aziz","year":"2015","journal-title":"Ocul Oncol Pathol"},{"issue":"2","key":"10.1016\/j.survophthal.2020.09.004_bib7","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.pathol.2015.12.005","article-title":"Satellite in transit metastases in rapidly fatal conjunctival melanoma: implications for angiotropism and extravascular migratory metastasis (description of a murine model for conjunctival melanoma)","volume":"48","author":"Barnhill","year":"2016","journal-title":"Pathology"},{"issue":"4","key":"10.1016\/j.survophthal.2020.09.004_bib8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1158\/1541-7786.MCR-16-0003","article-title":"Understanding TERT promoter mutations: a common path to immortality","volume":"14","author":"Bell","year":"2016","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.survophthal.2020.09.004_bib9","doi-asserted-by":"crossref","first-page":"100467","DOI":"10.1016\/j.ajoc.2019.100467","article-title":"Evaluation of interferon alpha 2b as adjunctive therapy for conjunctival melanoma","volume":"15","author":"Benage","year":"2019","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.survophthal.2020.09.004_bib10","first-page":"64","article-title":"Histologic features of conjunctival melanoma predictive of metastasis and death (an American Ophthalmological thesis)","volume":"110","author":"Esmaeli","year":"2012","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"3","key":"10.1016\/j.survophthal.2020.09.004_bib11","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/bjophthalmol-2018-312018","article-title":"Lack of tumour pigmentation in conjunctival melanoma is associated with light iris colour and worse prognosis","volume":"103","author":"Brouwer","year":"2019","journal-title":"Br J Ophthalmol"},{"issue":"33","key":"10.1016\/j.survophthal.2020.09.004_bib12","doi-asserted-by":"crossref","first-page":"54722","DOI":"10.18632\/oncotarget.18039","article-title":"PD-L1\/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma","volume":"8","author":"Cao","year":"2017","journal-title":"Oncotarget"},{"issue":"35","key":"10.1016\/j.survophthal.2020.09.004_bib13","doi-asserted-by":"crossref","first-page":"58021","DOI":"10.18632\/oncotarget.10770","article-title":"Targeting of the MAPK and AKT pathways in conjunctival melanoma shows potential synergy","volume":"8","author":"Cao","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.survophthal.2020.09.004_bib14","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.4103\/ijo.IJO_663_19","article-title":"Conjunctival melanoma with orbital invasion and liver metastasis managed with systemic immune checkpoint inhibitor therapy","volume":"67","author":"Chang","year":"2019","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.survophthal.2020.09.004_bib15","first-page":"349162","article-title":"The use of strontium-90 beta radiotherapy as adjuvant treatment for conjunctival melanoma","volume":"2013","author":"Cohen","year":"2013","journal-title":"J\u00a0Oncol"},{"issue":"12","key":"10.1016\/j.survophthal.2020.09.004_bib16","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1136\/bjophthalmol-2013-303671","article-title":"Prospective study of sentinel lymph node biopsy for conjunctival melanoma","volume":"97","author":"Cohen","year":"2013","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2020.09.004_bib17","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1097\/IOP.0000000000000833","article-title":"Conjunctival melanoma responsive to combined systemic BRAF\/MEK inhibitors","volume":"33","author":"Dagi Glass","year":"2017","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"17","key":"10.1016\/j.survophthal.2020.09.004_bib18","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1002\/cncr.31345","article-title":"Melanoma: what do all the mutations mean?","volume":"124","author":"Davis","year":"2018","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.survophthal.2020.09.004_bib19","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1001\/jamaophthalmol.2019.4237","article-title":"Integrative exome and transcriptome analysis of conjunctival melanoma and its potential application for personalized therapy","volume":"137","author":"Demirci","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2020.09.004_bib20","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.ophtha.2011.01.060","article-title":"Outcomes in 15 patients with conjunctival melanoma treated with adjuvant topical mitomycin C: complications and recurrences","volume":"118","author":"Ditta","year":"2011","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.survophthal.2020.09.004_bib21","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1167\/iovs.18-26508","article-title":"Conjunctival melanoma targeted therapy: MAPK and PI3K\/mTOR pathways inhibition","volume":"60","author":"El Zaoui","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.survophthal.2020.09.004_bib22","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1039\/C5MB00101C","article-title":"The PI3K\/AKT\/mTOR interactive pathway","volume":"11","author":"Ersahin","year":"2015","journal-title":"Mol Biosyst"},{"issue":"12","key":"10.1016\/j.survophthal.2020.09.004_bib23","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1097\/PAS.0000000000001344","article-title":"Greater tumor thickness, ulceration, and positive sentinel lymph node are associated with worse prognosis in patients with conjunctival melanoma: implications for future AJCC Classifications","volume":"43","author":"Esmaeli","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.survophthal.2020.09.004_bib24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ajo.2018.09.035","article-title":"Super-thick amniotic membrane graft for ocular surface reconstruction","volume":"198","author":"Finger","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2020.09.004_bib25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40425-019-0555-7","article-title":"Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series","volume":"7","author":"Finger","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"10.1016\/j.survophthal.2020.09.004_bib26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3109\/01676830.2015.1093509","article-title":"Evaluation of a short-term topical interferon \u03b1-2b treatment for histologically proven melanoma and primary acquired melanosis with atypia","volume":"35","author":"Garip","year":"2015","journal-title":"Orbit"},{"issue":"1","key":"10.1016\/j.survophthal.2020.09.004_bib27","article-title":"Anti-PD-1 and novel combinations in the treatment of melanoma-an update","volume":"9","author":"Gellrich","year":"2020","journal-title":"J\u00a0Clin Med"},{"issue":"1","key":"10.1016\/j.survophthal.2020.09.004_bib28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/bjophthalmol-2019-313977","article-title":"Incidence trends of conjunctival malignant melanoma in Canada","volume":"104","author":"Ghazawi","year":"2020","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2020.09.004_bib29","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/bjc.2013.312","article-title":"TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours","volume":"109","author":"Griewank","year":"2013","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.survophthal.2020.09.004_bib30","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1158\/1078-0432.CCR-13-0163","article-title":"Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas","volume":"19","author":"Griewank","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.survophthal.2020.09.004_bib31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mrrev.2016.11.002","article-title":"TERT promoter mutations in telomere biology","volume":"771","author":"Heidenreich","year":"2017","journal-title":"Mutat Res"},{"issue":"12","key":"10.1016\/j.survophthal.2020.09.004_bib32","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1016\/j.ophtha.2011.05.025","article-title":"Prognostic significance of tumor-associated lymphangiogenesis in malignant melanomas of the conjunctiva","volume":"118","author":"Heindl","year":"2011","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.survophthal.2020.09.004_bib33","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/IOP.0b013e31818be098","article-title":"Postoperative adjuvant external-beam radiation therapy for cancers of the eyelid and conjunctiva","volume":"24","author":"Hsu","year":"2008","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"3","key":"10.1016\/j.survophthal.2020.09.004_bib34","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ajo.2007.10.022","article-title":"Population-based incidence of conjunctival melanoma in various races and ethnic groups and comparison with other melanomas","volume":"145","author":"Hu","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2020.09.004_bib35","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/gcc.2870080307","article-title":"Chromosome 10 allelic loss in malignant melanoma","volume":"8","author":"Isshiki","year":"1993","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"10.1016\/j.survophthal.2020.09.004_bib36","first-page":"185","article-title":"Management of conjunctival malignant melanoma: a review and update","volume":"9","author":"James","year":"2014","journal-title":"Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2020.09.004_bib37","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s12943-019-1088-x","article-title":"m(6)A modification suppresses ocular melanoma through modulating HINT2 mRNA translation","volume":"18","author":"Jia","year":"2019","journal-title":"Mol Cancer"},{"issue":"3","key":"10.1016\/j.survophthal.2020.09.004_bib38","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/08820538.2019.1620793","article-title":"Conjunctival melanoma in asian indians: a study of 42 patients","volume":"34","author":"Kaliki","year":"2019","journal-title":"Semin Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2020.09.004_bib39","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/107327481602300205","article-title":"Management of primary acquired melanosis, nevus, and conjunctival melanoma","volume":"23","author":"Kao","year":"2016","journal-title":"Cancer Control"},{"issue":"4","key":"10.1016\/j.survophthal.2020.09.004_bib40","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1442-9071.2010.02469.x","article-title":"Conservative resection and adjuvant plaque brachytherapy for early-stage conjunctival melanoma","volume":"39","author":"Karim","year":"2011","journal-title":"Clin Exp Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2020.09.004_bib41","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s12253-018-0419-3","article-title":"Conjunctival Melanoma - Epidemiological Trends and Features","volume":"24","author":"Kastelan","year":"2018","journal-title":"Pathol Oncol Res"},{"issue":"4","key":"10.1016\/j.survophthal.2020.09.004_bib42","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/pcmr.12767","article-title":"Conjunctival melanoma copy number alterations and correlation with mutation status, tumor features, and clinical outcome","volume":"32","author":"Kenawy","year":"2019","journal-title":"Pigment Cell Melanoma Res"},{"issue":"11","key":"10.1016\/j.survophthal.2020.09.004_bib43","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1007\/s00417-017-3754-2","article-title":"Long-term follow-up of conjunctival melanoma treated with topical interferon alpha-2b eye drops as adjunctive therapy following surgical resection","volume":"255","author":"Kikuchi","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"23","key":"10.1016\/j.survophthal.2020.09.004_bib44","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1038\/onc.2016.486","article-title":"Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK\/PI3K inhibition or MEK\/CDK4\/6 inhibition","volume":"36","author":"Kim","year":"2017","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.survophthal.2020.09.004_bib45","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000497473","article-title":"Dabrafenib and trametinib for BRAF-mutated conjunctival melanoma","volume":"6","author":"Kim","year":"2020","journal-title":"Ocul Oncol Pathol"},{"issue":"3","key":"10.1016\/j.survophthal.2020.09.004_bib46","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2147\/OPTH.S1606","article-title":"Topical treatment options for conjunctival neoplasms","volume":"2","author":"Kim","year":"2008","journal-title":"Clin Ophthalmol"},{"issue":"8","key":"10.1016\/j.survophthal.2020.09.004_bib47","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jamaophthalmol.2017.2279","article-title":"Pembrolizumab for recurrent conjunctival melanoma","volume":"135","author":"Kini","year":"2017","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2020.09.004_bib48","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/ced.14060","article-title":"Two cases of BRAF-mutated, bulbar conjunctival melanoma, and review of the published literature","volume":"45","author":"Kiyohara","year":"2020","journal-title":"Clin Exp Dermatol"},{"issue":"9","key":"10.1016\/j.survophthal.2020.09.004_bib49","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1167\/iovs.14-14901","article-title":"Prevalence and implications ofTERTPromoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions","volume":"55","author":"Koopmans","year":"2014","journal-title":"Invest Opthalmology Vis Sci"},{"issue":"3","key":"10.1016\/j.survophthal.2020.09.004_bib50","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.tips.2020.01.001","article-title":"The interplay of the extracellular matrix and stromal cells as a drug target in stroma-rich cancers","volume":"41","author":"Kozlova","year":"2020","journal-title":"Trends Pharmacol Sci"},{"issue":"7","key":"10.1016\/j.survophthal.2020.09.004_bib51","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1055\/s-2008-1027432","volume":"225","author":"Krause","year":"2008","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"10.1016\/j.survophthal.2020.09.004_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/aos.13100","article-title":"Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile","volume":"94","author":"Larsen","year":"2016","journal-title":"Acta Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2020.09.004_bib53","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jamaophthalmol.2015.3200","article-title":"A\u00a0retrospective review of conjunctival melanoma presentation, treatment, and outcome and an investigation of features associated with BRAF mutations","volume":"133","author":"Larsen","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2020.09.004_bib54","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/aos.13007","article-title":"BRAF mutations in conjunctival melanoma: investigation of incidence, clinicopathological features, prognosis and paired premalignant lesions","volume":"94","author":"Larsen","year":"2016","journal-title":"Acta Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2020.09.004_bib55","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1167\/iovs.16-19862","article-title":"MicroRNA expression profile in conjunctival melanoma","volume":"57","author":"Larsen","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2020.09.004_bib56","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2147\/OPTH.S38415","article-title":"Conjunctival melanoma: a review of conceptual and treatment advances","volume":"6","author":"Lim","year":"2013","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2020.09.004_bib57","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/IOP.0b013e31822fb44b","article-title":"Sentinel lymph node biopsy in patients with conjunctival and eyelid cancers: experience in 17 patients","volume":"28","author":"Maalouf","year":"2012","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.survophthal.2020.09.004_bib58","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1186\/s12885-016-2657-7","article-title":"A\u00a0case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib","volume":"16","author":"Maleka","year":"2016","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.survophthal.2020.09.004_bib59","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jfo.2019.04.021","volume":"43","author":"Martel","year":"2020","journal-title":"J\u00a0Fr Ophtalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2020.09.004_bib60","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/ICO.0000000000000115","article-title":"Multifocal melanoma of the conjunctiva in an African American patient with neurofibromatosis type 1","volume":"33","author":"Medina Mendez","year":"2014","journal-title":"Cornea"},{"issue":"1","key":"10.1016\/j.survophthal.2020.09.004_bib61","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1167\/iovs.04-0344","article-title":"Conjunctival melanoma in the Netherlands: a nationwide study","volume":"46","author":"Missotten","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2020.09.004_bib62","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.2147\/OPTH.S187364","article-title":"Sentinel lymph node biopsy in the management of conjunctival melanoma: current insights","volume":"13","author":"Mor","year":"2019","journal-title":"Clin Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2020.09.004_bib63","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1073\/pnas.1919764117","article-title":"Combining microenvironment normalization strategies to improve cancer immunotherapy","volume":"117","author":"Mpekris","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.survophthal.2020.09.004_bib64","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/BF00448801","article-title":"Malignant melanoma of the conjunctiva: occurrence and survival following surgery and radiotherapy in a Danish population","volume":"234","author":"Norregaard","year":"1996","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6230","key":"10.1016\/j.survophthal.2020.09.004_bib65","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.survophthal.2020.09.004_bib66","article-title":"Conjunctival melanoma and BRAF inhibitor therapy","volume":"5","author":"Pahlitzsch","year":"2014","journal-title":"J\u00a0Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2020.09.004_bib67","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4274\/tjo.62681","article-title":"Amniotic membrane transplantation in surgical treatment of conjunctival melanoma: long-term results","volume":"48","author":"Palamar","year":"2018","journal-title":"Turk J Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2020.09.004_bib68","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1136\/bjo.78.7.520","article-title":"Orbital exenteration in 95 cases of primary conjunctival malignant melanoma","volume":"78","author":"Paridaens","year":"1994","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2020.09.004_bib69","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrc.2016.14","article-title":"Antitumour actions of interferons: implications for cancer therapy","volume":"16","author":"Parker","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.survophthal.2020.09.004_bib70","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1111\/aos.13252","article-title":"Sentinel lymph node biopsy for ocular adnexal melanoma","volume":"95","author":"Pfeiffer","year":"2017","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.survophthal.2020.09.004_bib71","first-page":"4623964","article-title":"Systemic treatment of metastatic conjunctival melanoma","volume":"2017","author":"Pinto Torres","year":"2017","journal-title":"Case Rep Oncol Med"},{"issue":"2","key":"10.1016\/j.survophthal.2020.09.004_bib72","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/CMR.0b013e32832ccd09","article-title":"Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma","volume":"20","author":"Populo","year":"2010","journal-title":"Melanoma Res"},{"issue":"12","key":"10.1016\/j.survophthal.2020.09.004_bib73","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/bjophthalmol-2015-306689","article-title":"B-Raf inhibition in conjunctival melanoma cell lines with PLX 4720","volume":"99","author":"Riechardt","year":"2015","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2020.09.004_bib74","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/jhg.2015.152","article-title":"UV light signature in conjunctival melanoma; not only skin should be protected from solar radiation","volume":"61","author":"Rivolta","year":"2015","journal-title":"J\u00a0Hum Genet"},{"issue":"2","key":"10.1016\/j.survophthal.2020.09.004_bib75","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/00003226-200303000-00006","article-title":"Topical mitomycin C in the treatment of pigmented conjunctival lesions","volume":"22","author":"Rodr\u00edguez-Ares","year":"2003","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2020.09.004_bib76","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3389\/fonc.2019.00232","article-title":"Dabrafenib and trametinib in BRAF mutant metastatic conjunctival melanoma","volume":"9","author":"Rossi","year":"2019","journal-title":"Front Oncol"},{"issue":"21","key":"10.1016\/j.survophthal.2020.09.004_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20215447","article-title":"Conjunctival melanoma: genetic and epigenetic insights of a distinct type of melanoma","volume":"20","author":"Rossi","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.survophthal.2020.09.004_bib78","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/IOP.0000000000000096","article-title":"Indocyanine green-guided sentinel lymph node biopsy for periocular tumors","volume":"30","author":"Rubinstein","year":"2014","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"1","key":"10.1016\/j.survophthal.2020.09.004_bib79","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.survophthal.2014.08.001","article-title":"Desmoplastic melanoma of the eyelid and conjunctival melanoma in neurofibromatosis type 1: a clinical pathological correlation","volume":"60","author":"Rubinstein","year":"2015","journal-title":"Surv Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2020.09.004_bib80","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1136\/bjo.2009.176099","article-title":"Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications","volume":"94","author":"Russell","year":"2010","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2020.09.004_bib81","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/jamaophthalmol.2018.3488","article-title":"Immunotherapy with programmed cell death 1 inhibitors for 5 patients with conjunctival melanoma","volume":"136","author":"Sagiv","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2020.09.004_bib82","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/j.ophtha.2009.04.012","article-title":"Sentinel lymph node biopsy for ocular adnexal melanoma: experience in 30 patients","volume":"116","author":"Savar","year":"2009","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.survophthal.2020.09.004_bib83","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/s41416-018-0046-5","article-title":"NF1 mutations in conjunctival melanoma","volume":"118","author":"Scholz","year":"2018","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.survophthal.2020.09.004_bib84","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s00417-019-04286-2","article-title":"Proton radiotherapy in advanced malignant melanoma of the conjunctiva","volume":"257","author":"Scholz","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6024","key":"10.1016\/j.survophthal.2020.09.004_bib85","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.survophthal.2020.09.004_bib86","first-page":"3399","article-title":"Population-based assessment of clinical characteristics predicting outcome of conjunctival melanoma in whites","volume":"43","author":"Tuomaala","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.survophthal.2020.09.004_bib87","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0039-6257(97)00122-7","article-title":"Conjunctival melanoma","volume":"42","author":"Seregard","year":"1998","journal-title":"Surv Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2020.09.004_bib88","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/0008-5472.CAN-04-2423","article-title":"Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors","volume":"65","author":"Sharma","year":"2005","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.survophthal.2020.09.004_bib89","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1001\/archopht.118.11.1497","article-title":"Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients","volume":"118","author":"Shields","year":"2000","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2020.09.004_bib90","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ophtha.2010.06.021","article-title":"Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases","volume":"118","author":"Shields","year":"2011","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.survophthal.2020.09.004_bib91","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/IOP.0b013e3182611670","article-title":"American Joint Committee on Cancer (AJCC) clinical classification predicts conjunctival melanoma outcomes","volume":"28","author":"Shields","year":"2012","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"6","key":"10.1016\/j.survophthal.2020.09.004_bib92","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1001\/archopht.1997.01100150810025","article-title":"Surgical management of conjunctival tumors. The 1994 Lynn B. McMahan Lecture","volume":"115","author":"Shields","year":"1997","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2020.09.004_bib93","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0161-6420(00)00061-0","article-title":"Malignant melanoma of the eyelid and palpebral conjunctiva treated with iodine-125 brachytherapy","volume":"107","author":"Stannard","year":"2000","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.survophthal.2020.09.004_bib94","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1001\/jamaophthalmol.2017.4837","article-title":"Molecular characteristics of conjunctival melanoma using whole-exome sequencing","volume":"135","author":"Swaminathan","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.survophthal.2020.09.004_bib95","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.addr.2016.09.002","article-title":"Advancements in brachytherapy","volume":"109","author":"Tanderup","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/j.survophthal.2020.09.004_bib96","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.survophthal.2016.06.001","article-title":"Advances in the management of conjunctival melanoma","volume":"62","author":"Vora","year":"2017","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.survophthal.2020.09.004_bib97","first-page":"1","article-title":"Sentinel lymph node biopsy for conjunctival malignant melanoma: surgical techniques","volume":"9","author":"Wainstein","year":"2015","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2020.09.004_bib98","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1442-9071.2009.02092.x","article-title":"Plaque brachytherapy for the management of ocular surface malignancies with corneoscleral invasion","volume":"37","author":"Walsh-Conway","year":"2009","journal-title":"Clin Exp Ophthalmol"},{"issue":"22","key":"10.1016\/j.survophthal.2020.09.004_bib99","doi-asserted-by":"crossref","first-page":"6329","DOI":"10.1158\/1078-0432.CCR-13-2007","article-title":"Conjunctival melanomas harbor BRAF and NRAS mutations--Letter","volume":"19","author":"Weber","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.survophthal.2020.09.004_bib100","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s00417-005-0093-5","article-title":"Proton radiotherapy as an alternative to exenteration in the management of extended conjunctival melanoma","volume":"244","author":"Wuestemeyer","year":"2006","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2020.09.004_bib101","first-page":"286","article-title":"Genetic and epigenetic biomarkers of immune checkpoint blockade response","volume":"9","author":"Xiao","year":"2020","journal-title":"J\u00a0Clin Med"},{"issue":"9","key":"10.1016\/j.survophthal.2020.09.004_bib102","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1172\/JCI83871","article-title":"Cancer immunotherapy: harnessing the immune\u00a0system to battle cancer","volume":"125","author":"Yang","year":"2015","journal-title":"J\u00a0Clin Invest"},{"issue":"12","key":"10.1016\/j.survophthal.2020.09.004_bib103","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1167\/iovs.17-22376","article-title":"Conjunctival melanoma in chinese patients: local recurrence, metastasis, mortality, and comparisons with caucasian patients","volume":"58","author":"Zhou","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003962572030134X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003962572030134X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T11:49:36Z","timestamp":1758541776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003962572030134X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":103,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S003962572030134X"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2020.09.004","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical treatment options for early-stage and advanced conjunctival melanoma","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2020.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}